文献速递炎症性肠病

儿童起病炎症性肠病中的IL-10中和性自身抗体

IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease.
PubMed 文献 · Gut · 2026-07-08

该研究在儿童起病IBD、自身免疫性肠病及先天性腹泻患儿中检测血浆IL-10自身抗体,发现5例具有IL-10中和活性的自身抗体,均见于无已知单基因病因的IBD患者,患病率为2.1%(95%CI 0.7%至4.8%)。抗体在标准免疫抑制治疗下持续存在,但在造血干细胞移植后消失。

要点

  • 儿童IBD中IL-10中和性自身抗体患病率为2.1%,仅见于无已知单基因病因者。
  • 该抗体在标准免疫抑制治疗下可持续存在,HSCT后消失。
  • 功能性检测筛查IL-10自身抗体可能识别出病因和治疗需求不同的IBD亚组。

核心结论

  • 在儿童自身免疫性和炎症性肠道疾病中,IL-10中和性自身抗体仅见于无已知遗传病因的IBD患者,提示该抗体可能标识一个病因独特的IBD亚组。

研究设计与样本

  • 横断面研究纳入儿童起病IBD患者239例、自身免疫性肠病患者37例及先天性腹泻和肠病患者42例,检测血浆IL-10自身抗体并进行细胞功能性试验。

主要发现

  • 共鉴定出5例患者具有中和2.5 ng/mL IL-10的自身抗体,其中3例在5 ng/mL时仍具中和活性,所有5例均为无已知单基因病因的IBD患者。
  • 5例中3例有纵向样本,2例自身抗体在基线后3年和9年持续存在,另1例在基线后2年接受HSCT后抗体消失。
  • 中和性IL-10自身抗体的患病率为2.1%(95%CI 0.7%至4.8%),在无IBD相关单基因变异的受试者(n=192)中频率为2.6%。

关键数值与推荐

  • IL-10中和性自身抗体患病率为2.1%(95%CI 0.7%至4.8%)。
  • 无IBD相关单基因变异受试者中自身抗体频率为2.6%(n=192)。
  • 5例中3例在5 ng/mL IL-10时仍显示中和活性。

临床怎么用

  • 对于无已知单基因病因的儿童起病IBD,可考虑通过功能性检测筛查IL-10中和性自身抗体以识别特定亚组。
  • 该抗体在标准免疫抑制治疗下可能持续存在,HSCT后消失,结肠切除或回肠造口后可能下降。

局限性

  • 纵向样本仅3例可用,抗体长期持久性和治疗影响的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoantibodies neutralising interleukin-10 (IL-10) have recently been described as a mechanism of inflammatory bowel disease (IBD); however, prevalence and clinical impacts are unknown. OBJECTIVE: To determine the prevalence and longitudinal persistence of IL-10 autoantibodies in a population of paediatric-onset IBD and to assess associated clinical features. DESIGN: We analysed plasma IL-10 autoantibodies with a cross-sectional study of a paediatric cohort of patients diagnosed with either IBD (n=239), autoimmune enteropathy (n=37) or congenital diarrhoea and enteropathies (n=42). Functional testing to assess IL-10 response was performed using cell-based assays under biologically relevant stimulation. RESULTS: Five patients with autoantibodies neutralising 2.5 ng/mL of IL-10 were identified, three of whom were also neutralising at 5 ng/mL. All had IBD without a known monogenic cause. Longitudinal samples (available in three of five subjects) showed autoantibody persistence in two cases, 3 and 9 years after baseline. The patient without persistence had undergone haematopoietic stem-cell transplantation (HSCT) 2 years after baseline sampling. The prevalence of neutralising IL-10 autoantibodies was 2.1% (95% CI 0.7% to 4.8%), while the frequency was 2.6% in subjects without IBD-associated monogenic variants (n=192). CONCLUSION: In paediatric autoimmune and inflammatory gut diseases, IL-10 neutralising autoantibodies were detected only among patients with IBD without known genetic aetiology. Patients had heterogeneous clinical characteristics and IL-10 autoantibodies persisted under standard immunosuppressive treatment but disappeared following HSCT and may have declined with colectomy or ileostomy. Screening for IL-10 autoantibodies via functional assays may identify a subgroup of patients with distinct aetiology and therapeutic needs.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Yalcinkaya A, Sandström E, Degrace EJ, et al. IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease. Gut. 2026. PMID: 42419823. doi:10.1136/gutjnl-2026-338876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。